Effects of Pulmonary Rehabilitation on Walking Speed in Patients With COPD or ILD Patients

NCT ID: NCT04159129

Last Updated: 2019-11-22

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Total Enrollment

43 participants

Study Classification

OBSERVATIONAL

Study Start Date

2019-11-07

Study Completion Date

2020-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The aim of this study is to evaluate the effects of a three-week inpatient pulmonary rehabilitation (PR) program on the walking speed in patients with chronic obstructive (COPD) or interstitial lung disease (ILD).

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

At most german traffic light crossings, a walking speed of 1,2m/sec is required to cross the road in time. Patients who are unable to cross the road at this speed, expose themselves to an increased level of stress and possibly the risk of accidents. Thus, they are discouraged from participating in an active social life.

An UK study (Nolan et al., Thorax 2018) showed that only 10.7% of the 926 patients with moderate COPD attained a walking speed of 1.2m/sec. As PR plays a key role in the management of chronic lung diseases in order to improve patients´ exercise capacity, the aim of this study was to evaluate the PR effects on the Walking Speed in patients with COPD or ILD. The investigators hypothesize that PR improves the ability to cross the road in the appropriate time.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pulmonary Disease, Chronic Obstructive Lung Diseases, Interstitial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Participation in a pulmonary Rehabilitation program (Schön Klinik BGL)
* Indication: COPD or ILD
* COPD; FEV1 \<50%
* ILD: FVC \<70%
* written informed consent

Exclusion Criteria

* non compliance
Minimum Eligible Age

40 Years

Maximum Eligible Age

85 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Psychologische Hochschule Berlin

UNKNOWN

Sponsor Role collaborator

Schön Klinik Berchtesgadener Land

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Klaus Kenn

Prof. Dr. Klaus Kenn

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Klaus Kenn, Prof.

Role: PRINCIPAL_INVESTIGATOR

Schön Klinik Berchtesgadener Land

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Schön Klinikum Berchtesgadener Land

Schönau am Königssee, Bavaria, Germany

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Germany

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Klaus Kenn, Prof.

Role: CONTACT

0049865293 ext. 1730

Inga Jarosch, PhD

Role: CONTACT

0049865293 ext. 1730

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Klaus Kenn, Dr. med.

Role: primary

0049-8652-93 ext. 1540

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ampel2019

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.